Insider Selling: Privia Health Group (NASDAQ:PRVA) Director Sells $1,601,159.96 in Stock

Privia Health Group, Inc. (NASDAQ:PRVA) Director Matthew Shawn Morris sold 63,212 shares of Privia Health Group stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $25.33, for a total value of $1,601,159.96. Following the completion of the sale, the director owned 76,651 shares of the company’s stock, valued at $1,941,569.83. The trade was a 45.20% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Matthew Shawn Morris also recently made the following trade(s):

• On Friday, June 26th, Matthew Shawn Morris sold 88,110 shares of Privia Health Group stock. The stock was sold at an average price of $25.33, for a total transaction of $2,231,826.30.
• On Friday, May 1st, Matthew Shawn Morris sold 17,096 shares of Privia Health Group stock. The shares were sold at an average price of $24.99, for a total transaction of $427,229.04.
• On Monday, May 4th, Matthew Shawn Morris sold 1,017 shares of Privia Health Group stock. The shares were sold at an average price of $24.96, for a total transaction of $25,384.32.

Privia Health Group Stock Performance

NASDAQ:PRVA opened at $27.36 on Friday. The firm has a 50-day simple moving average of $23.38 and a 200-day simple moving average of $22.99. Privia Health Group, Inc. has a one year low of $18.77 and a one year high of $27.52. The firm has a market cap of $3.45 billion, a P/E ratio of 171.01, a P/E/G ratio of 2.13 and a beta of 0.83.

Privia Health Group (NASDAQ:PRVA) last released its quarterly earnings data on Thursday, May 7th. The company reported $0.19 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.08 by $0.11. The firm had revenue of $603.85 million for the quarter, compared to the consensus estimate of $560.99 million. Privia Health Group had a net margin of 0.97% and a return on equity of 2.81%. The company’s quarterly revenue was up 25.8% on a year-over-year basis. During the same period last year, the firm earned $0.22 earnings per share. On average, research analysts predict that Privia Health Group, Inc. will post 0.27 EPS for the current fiscal year.

Institutional Trading of Privia Health Group

Institutional investors have recently bought and sold shares of the stock. Bayban purchased a new position in shares of Privia Health Group in the fourth quarter worth $26,000. Hantz Financial Services Inc. boosted its holdings in Privia Health Group by 456.2% during the fourth quarter. Hantz Financial Services Inc. now owns 1,129 shares of the company’s stock worth $27,000 after buying an additional 926 shares in the last quarter. Global Retirement Partners LLC boosted its stake in shares of Privia Health Group by 579.8% during the 4th quarter. Global Retirement Partners LLC now owns 1,584 shares of the company’s stock worth $38,000 after acquiring an additional 1,351 shares in the last quarter. Canada Pension Plan Investment Board boosted its position in Privia Health Group by 48.0% during the second quarter. Canada Pension Plan Investment Board now owns 3,700 shares of the company’s stock worth $85,000 after purchasing an additional 1,200 shares in the last quarter. Finally, Kestra Advisory Services LLC purchased a new position in shares of Privia Health Group during the 4th quarter valued at approximately $93,000. 94.48% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several analysts have issued reports on PRVA shares. Barclays dropped their target price on Privia Health Group from $25.00 to $24.00 and set an “equal weight” rating on the stock in a research report on Tuesday, May 26th. Evercore set a $26.00 price objective on Privia Health Group in a research note on Wednesday, April 8th. Weiss Ratings downgraded Privia Health Group from a “hold (c)” rating to a “hold (c-)” rating in a research report on Friday, May 8th. Finally, Canaccord Genuity Group cut their target price on Privia Health Group from $35.00 to $34.00 and set a “buy” rating on the stock in a research note on Friday, May 8th. Eleven equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $31.15.

Privia Health Group Company Profile

Privia Health Group (NASDAQ: PRVA) is a physician enablement company that partners with independent physicians, medical groups and health systems to transform the delivery of patient care. Through a clinically integrated network and a proprietary technology platform, the company supports providers in managing population health, delivering coordinated care and optimizing financial performance under both fee-for-service and value-based reimbursement models.

Founded in 2016 and headquartered in McLean, Virginia, Privia Health has rapidly expanded its footprint to serve multiple metropolitan markets across the United States.